RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Guangdong Provincial People's Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07016126, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07016126, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Only patients who meet all of the following criteria are eligible for inclusion in this study:

Provide written informed consent Male or female, aged 18 to 75 years Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Measurable disease in accordance with RECIST version 1.1

Subjects must be able to provide a specimen containing tumor tissue or have a newly resected tumor biopsy sample available for PD-L1 immunohistochemistry (IHC) testing at a central laboratory during the screening phase:

Before treatment, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or unstained tumor tissue sections and relevant pathology reports must be submitted for biomarker assessment. Tumor tissue specimens may be fresh or archived within 6 months before enrollment.

The tissue must be a core needle biopsy section, excisional biopsy section, or incisional biopsy section.

It is recommended that fresh paraffin sections (PD-L1 assay to be performed within 7 days of sectioning) be stored and transported in the dark.

It is recommended that fresh tissue be fixed in 10% neutral buffered formalin for 24 to 48 hours.

The patient's lung function or other organ function must be evaluated by a surgeon as adequate to tolerate local surgical treatment.

Adequate organ function assessment and laboratory screening must be performed within 7 days prior to initiation of therapy.

Reproductive status:

Women of childbearing potential must have a negative pregnancy test (serum or urine) within 72 hours before the start of treatment.

Women must be non-lactating. Female patients must use appropriate contraception during treatment and for 6 months after the last dose of treatment.

Male subjects must agree to use appropriate contraception during treatment and for 7 months after the last dose of treatment, and must be willing to avoid donating sperm during this period.

Exclusion Criteria:

Medical conditions Stage I, IIIB/IIIC (N3), and stage IV NSCLC. Patients with previous immune checkpoint inhibitor (ICI) immunotherapy, targeted therapy, chemotherapy, or other systemic antitumor therapies.

Patients with brain metastases. Patients with allergy to contrast media. Patients whose tumors have targeted alterations in EGFR and/or ALK, or known targeted alterations in ROS1, BRAF, HER-2, NTRK, MET, or RET. Patients with K-RAS mutations are eligible.

Active known or suspected autoimmune disease. Subjects are eligible if they have type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or other conditions not expected to recur in the absence of an external trigger.

Patients with active hepatitis B (positive hepatitis B surface antigen [HBsAg] test) or hepatitis C (positive HCV RNA test). Patients with previous HBV infection or resolved HBV infection (defined as positive hepatitis B core antibody [HBcAb] and negative HBsAg) are eligible to participate; these patients must provide HBV DNA test results before enrollment. Patients who are HBV carriers or require antiviral therapy are not eligible. Patients who test positive for HCV antibodies are eligible only if they have negative HCV RNA by PCR.

Patients with a history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).

Any history of arterial thrombosis within 6 months. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months.

Uncontrolled angina, arrhythmia, or congestive heart failure. Other active malignancy within 5 years (except adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, superficial bladder cancer, prostate cancer, or breast carcinoma in situ).

Patients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.

Serious or uncontrolled medical illness. Patients with psychosis or other conditions resulting in treatment nonadherence.

History of severe hypersensitivity reactions to other monoclonal antibodies. Patients who are unwilling to sign the informed consent form. Patients who are unwilling to undergo follow-up. Physical and laboratory examinations

Laboratory screening values must not meet any of the following criteria (CTCAE version 5.0 applies):

Bone marrow function:

White blood cell count < 2,000/μL Neutrophil count < 1,500/μL Platelet count < 100 × 10³/μL Hemoglobin < 9.0 g/dL

Liver function:

Serum total bilirubin > 1.5 times the upper limit of normal (ULN) In the presence of liver metastases, AST and ALT > 5 × ULN, and total bilirubin > 1.5 × ULN

Coagulation function:

Abnormal coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN; if the subject is receiving anticoagulant therapy, PT must be outside the intended therapeutic range of the anticoagulant drug.

Renal function:

Urine protein > 2+, or 24-hour urinary protein ≥ 1 g Serum creatinine > 1.5 × ULN, or calculated creatinine clearance (CrCl) < 50 mL/min (using the Cockcroft-Gault formula) Female CrCl = ([140 - age] × weight [kg] × 0.85) / (72 × serum creatinine [mg/dL]) Male CrCl = ([140 - age] × weight [kg] × 1.00) / (72 × serum creatinine [mg/dL]) Allergy and drug hypersensitivity History of hypersensitivity to other monoclonal antibodies. History of allergic or hypersensitivity reactions to components of the study drugs.

Other exclusion criteria Prisoners or subjects under compulsory confinement. Subjects involuntarily detained for treatment of mental or physical illness (e.g., infectious disease).

Quoted from ClinicalTrials.gov, NCT07016126, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07016126, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07016126